{"nctId":"NCT04335591","briefTitle":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)","startDateStruct":{"date":"2020-03-05","type":"ACTUAL"},"conditions":["Endometriosis"],"count":356,"armGroups":[{"label":"Linzagolix 75 mg","type":"EXPERIMENTAL","interventionNames":["Drug: 75 mg linzagolix tablet","Drug: Placebo tablet to match 200 mg linzagolix tablet","Drug: Placebo capsule to match Add-back capsule"]},{"label":"Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: 200 mg linzagolix tablet","Drug: Placebo tablet to match 75 mg linzagolix tablet","Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)"]}],"interventions":[{"name":"75 mg linzagolix tablet","otherNames":[]},{"name":"200 mg linzagolix tablet","otherNames":[]},{"name":"Placebo tablet to match 75 mg linzagolix tablet","otherNames":[]},{"name":"Placebo tablet to match 200 mg linzagolix tablet","otherNames":[]},{"name":"Add-back capsule (E2 1 mg / NETA 0.5 mg)","otherNames":[]},{"name":"Placebo capsule to match Add-back capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nThe subject must have:\n\n* completed the 6-month treatment in the main study.\n* agree to continue to use only the analgesic rescue medication permitted by the protocol during the Treatment and Follow-up Periods.\n* To continue to comply with the requirements of the study protocol for the duration of the extension study.\n\nExclusion Criteria:\n\nThe subject will be excluded if she:\n\n* Is pregnant or breast feeding or is planning a pregnancy within the duration of the of the study (including the Follow-up Period).\n* likely to require treatment during the study with any of the restricted medications\n* has any other clinically significant gynecologic condition identified during the main study on transvaginal ultrasound (TVUS), on endometrial biopsy or at the manual breast examination, which might interfere with the study efficacy and safety objectives.\n* met any of the main study discontinuation criteria","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"genderDescription":"Females Only","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Dysmenorrhea","description":"Proportion of subjects with reduction of DYS (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"43","spread":null}]}]}]},{"type":"PRIMARY","title":"Non-menstrual Pelvic Pain","description":"Proportion of subjects with reduction of NMPP (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":119},"commonTop":["COVID-19","Headache","Hot flush","Anaemia","Vaginal haemorrhage"]}}}